Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine

Related Experiment Videos

Rosa Roldan1, Adela M Ruiz, Maria D Miranda

  • 1Rheumatology Department, Reina Sofia Hospital, Avenida Menendez Pidal s/n, 14004 Cordoba, Spain. peperosa@teleline.es

Joint Bone Spine
|June 11, 2008
PubMed

Insights

Familial Mediterranean fever (FMF) is an autoinflammatory disorder. Anakinra, an interleukin-1 receptor antagonist, effectively treated a child with therapy-resistant FMF, resolving inflammation and potentially reducing amyloidosis risk.

Area of Science:

  • Immunology
  • Genetics
  • Rheumatology

Background:

  • Familial Mediterranean fever (FMF) is a recessively inherited autoinflammatory disorder characterized by recurrent inflammation.
  • FMF can lead to systemic AA protein deposition and amyloidosis, posing a significant health risk.
  • Pyrin mutations regulate IL-1beta production, a key inflammatory mediator in FMF.

Observation:

  • Colchicine is the standard FMF treatment, but some patients exhibit resistance or intolerance.
  • Anticytokine therapies are emerging treatments for autoinflammatory conditions.
  • A child with therapy-resistant FMF was treated with anakinra, an interleukin-1 receptor antagonist.

Findings:

  • Anakinra treatment led to immediate and sustained resolution of FMF symptoms.
  • Laboratory markers of inflammation significantly improved following anakinra administration.
  • The treatment may potentially reduce the long-term risk of AA amyloidosis in FMF patients.

Implications:

  • Anakinra represents a promising therapeutic option for FMF patients unresponsive to conventional treatments.
  • Targeting IL-1beta with anakinra may offer a new strategy for managing FMF and preventing its severe complications.
  • This case highlights the potential of targeted biologic therapies in managing complex autoinflammatory diseases.

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...